STRIANT net product revenues were $0.2 million reduce than in the second quarter of 2010 as a result of the sale to Actient. Total royalties were $0.7 million in the next quarter of 2011. There were no royalty revenues in the second quarter of 2010. Royalties on sales by Watson had been around $0.6 million, in comparison to approximately $0.5 million in the first quarter of 2011. Gross profit %age was 84 percent in the second quarter of 2011, compared to 78 percent in the next quarter of 2010, including the acknowledgement of the deferred gain on the sale of the progesterone possessions to Watson and the $5.0 million milestone payment from Watson. Excluding the deferred gain acknowledgement and the milestone payment, the gross profit margin for the second quarter of 2011 could have been 47 percent, primarily reflecting the product sales to Watson on a cost-plus-10 percent basis and lower unit prices to Merck Serono.To meet this market need and client demand, Celerion produced significant investments to put into action intensive staff training and added leading edge technology. The trained staff fully, in combination with state-of-the-art analyzers, has produced unparalleled precision. Important Equally, by deploying this technology, Celerion has been able to increase cohort size on research needing platelet aggregation, from eight to 40 individuals, creating performance in the conduct of these studies. ‘Reaching this milestone can be a testament to Celerion’s ability to respond to the evolving needs of early clinical research,’ stated Phil Bach, Vice President, Global Clinical Research. ‘Our experience has already benefited many customers in producing high quality data efficiently, to greatly help them achieve their goal of getting products to market sooner.’..